Screening of GPCR drugs for repurposing in breast cancer.
Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S, Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Park JH, Johnson CA, Kaipparettu BA, Bond RA, Johnson M, Stephan C, Trivedi MV.
Abdulkareem NM, et al. Among authors: johnson ca.
Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640. eCollection 2022.
Front Pharmacol. 2022.
PMID: 36561339
Free PMC article.
We focused on beta-adrenergic receptor-targeting nebivolol as a candidate, primarily because of the potential role of these receptors in BC and its excellent long-term safety profile. The effects of nebivolol were validated in an independent assay in all the cell line mode …
We focused on beta-adrenergic receptor-targeting nebivolol as a candidate, primarily because of the potential role of these receptors in BC …